AnaCardio receives IND approval from the FDA for AC01 to Start a Clinical Pharmacology Study

Stockholm, Sweden, August 17, 2023  AnaCardio, a Swedish clinical-stage biopharmaceutical company focussing on developing novel  contractile agents to treat patients with heart failure, today announced that the U.S. Food and  Drug Administration (FDA) has granted the company’s Investigational New Drug (IND)  application for the investigational drug AC01. The approval enables expansion of the clinical  development […]